melanotan articles ↓

Clinuvel has  announced positive interim Phase III results from the first of the trialists to complete a 12 month study in Switzerland. The 14 patients in Switzerland will form part of 101 to undergo long term study around the world. Further participants and …

The mainstream UK press has several articles today about the risks of an using a yet to be approved injectible tan, even go so far as to name Melanotan. The Independent: Warnings over ‘injectable tan’ product People seeking a glow this winter should avoid an "injectable tan" being sold illegally, regulators warned today. The Medicines …

Perhaps Clinuvel is best known as the Australian company that is developing Afamelanotide. As some background: Melanotan is the proprietary name for afamelanotide (CUV1647) which is being development by Clinuvel Pharmaceuticals. Afamelanotide has been designated by the world health organisation as the International Nonproprietary Name for the melanocyte stimulating hormone under development by Clinuvel. Clinuvel is promoting this drug as a …

Clinuvel Pharmaceuticals has announced that they have been granted orphan-drug status by the FDA to treat the skin condition erythropoietic porphyrias. Orphan drug status is granted to new drugs that treat rare conditions and is used as an instrument to obtain accelerated review by the FDA. The FDA allows tax reductions and market exclusivity …

Getting some press in Australia currently is a story about a trial starting today in Melbourne. The trial will assess the efficacy of CUV1647 (also known as melanotan) to protect against skin cancer in patients who have had organ transplants. Patients who have received organ transplants are at a much higher risk of contracting skin cancer because of the immune suppressive drugs that they …